Rejected from eLife? The 7 Best Journals to Submit Next

eLife's editorial model has two distinct failure points, and they mean very different things for your next submission.

This is where most rejections happen. A senior editor and reviewing editor evaluate whether the paper merits public review. They're asking one question: does this paper present a conceptual advance that will interest biologists outside the immediate subfield? If both editors say no, the paper doesn't proceed.

Common reasons at this stage include the following.

• "Incremental advance within the field." Your experiments are solid, but the findings confirm or extend what the community already expected. eLife wants papers that shift understanding, not ones that fill gaps in existing frameworks.

• "Too specialized for eLife's readership." You've done excellent work in a narrow subdiscipline, but the editors don't think researchers outside that niche will engage with it. A paper on a specific signaling pathway in a rare cell type might be excellent science but lack the broad interest eLife requires.

• "Incomplete mechanistic story." eLife expects a complete narrative. If your paper identifies a phenomenon but doesn't explain the mechanism, or proposes a mechanism without sufficient experimental validation, the editors will flag this at screening.

If your paper passed screening and received reviews but the assessment was negative, that's actually a better position. The public reviews tell you exactly what needs to change. In eLife's system, those reviews are attached to the Reviewed Preprint permanently, which means you have a public record of expert evaluation. Some authors worry that negative public reviews will harm them, but in practice, a published preprint with substantive reviews attached demonstrates your work was taken seriously.

• "The key claims aren't fully supported." Reviewers found experimental gaps. Perhaps a control was missing, a statistical approach was questionable, or the data didn't fully support the headline conclusion.

• "The biological significance isn't clear." Your experiments worked, but the reviewers didn't see why the findings matter for the broader field. This is a framing problem as much as a data problem.

Before choosing your next journal, a eLife manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

1. PLOS Biology

PLOS Biology is the closest philosophical match to eLife. Both journals are open-access, both prioritize conceptual advances over technical increments, and both attract a broad biology readership. The main difference is that PLOS Biology uses traditional peer review rather than eLife's public model, and its acceptance rate is slightly higher.

If eLife rejected your paper at screening for being "too specialized," PLOS Biology may still find it interesting enough for their readership. The editorial bar is high, but the scope is genuinely broad. PLOS Biology also publishes strong methods papers and resource articles that eLife sometimes screens out for lacking a biological discovery angle.

Best for: Open-access biology papers with conceptual novelty, systems biology, ecology, evolutionary biology.

2. EMBO Journal

For molecular and cell biology specifically, EMBO Journal is a top-tier alternative. The journal values mechanistic depth and expects well-controlled biochemistry, structural biology, or cell biology experiments. If eLife's rejection was about the story being too specialized for a general biology audience, EMBO Journal's more focused readership might be exactly right.

EMBO Journal's editorial process is also fast. Desk decisions typically come within a week, and the journal has a transparent peer review option. One practical advantage: EMBO Journal shares a review cascade with EMBO Reports, so a rejection from EMBO Journal can lead to a direct transfer.

Best for: Mechanistic molecular biology, structural biology, signal transduction, gene regulation.

3. Nature Communications

Nature Communications publishes across all natural sciences and has the volume to consider a wider range of papers than most high-IF journals. If eLife screened out your paper but you believe the data is strong, Nature Communications is a reasonable next step. The journal accepts around 8% of submissions, which is selective, but it publishes thousands of papers per year across biology, physics, chemistry, and earth sciences.

The trade-off is cost. Nature Communications charges $7,350 for open access, which is among the highest APCs in biology publishing. For well-funded labs, that's manageable. For early-career researchers or labs in lower-income countries, it's a real barrier.

Best for: Strong interdisciplinary work, biology papers with physics or chemistry overlap, large-scale datasets.

4. PNAS

PNAS occupies a unique space as a broad-scope, multidisciplinary journal with a slightly different editorial model. The journal accepts contributed articles from NAS members and direct submissions, though the contributed track has been narrowed in recent years. For papers that cross traditional disciplinary boundaries, PNAS is an excellent venue because the readership includes scientists from all fields.

If eLife rejected your paper because it sits at the intersection of two fields and didn't fit cleanly into one editorial board's expertise, PNAS's multidisciplinary structure may work better.

Best for: Cross-disciplinary biological research, biophysics, computational biology, evolution and ecology.

5. Journal of Cell Biology

JCB is the premier cell biology journal, published by Rockefeller University Press. If your eLife submission was a cell biology paper and the rejection centered on the work being too specialized for a general audience, JCB's readership is that specialized audience. The journal publishes outstanding imaging-based research, organelle biology, cytoskeleton studies, and membrane trafficking work.

JCB also has a strong commitment to data transparency and requires authors to share raw data. If your paper has excellent microscopy or imaging data, JCB's editors will appreciate that.

Best for: Cell biology, live-cell imaging, organelle dynamics, cytoskeleton research, membrane biology.

6. Current Biology

Current Biology publishes short-format papers across all areas of biology, with a particular strength in evolutionary biology, neuroscience, and animal behavior. The journal likes papers that tell a clean, surprising story in a compact format. If your eLife submission was a focused study with a clear punchline, Current Biology's format might suit it well.

The journal doesn't charge APCs for research articles (it's published by Cell Press under a subscription model), which makes it attractive for labs without large publication budgets.

Best for: Short, complete biology stories, behavioral biology, evolutionary biology, neuroscience.

7. EMBO Reports

EMBO Reports publishes shorter molecular biology and cell biology papers that don't quite fit the full-length format of EMBO Journal. If your paper is strong but the story is compact, or if EMBO Journal rejected it as "more suited to a shorter format," EMBO Reports is the natural landing spot.

The journal also accepts scientific commentary and policy-related articles, but its research papers are the most relevant for eLife refugees. Review times are reasonable, typically six to ten weeks.

Best for: Shorter molecular biology studies, preliminary mechanistic findings, cell biology with a focused scope.

Screened out for being too specialized? Try EMBO Journal or JCB for molecular and cell biology, or a discipline-specific journal in your field (Journal of Neuroscience for neuro, Genetics for genetics, etc.). Your paper isn't bad. It's just aimed at too narrow an audience for a general biology journal.

Negative assessment after public review? Read the public reviews carefully. If the concerns are addressable, revise and resubmit to eLife with a detailed response. The public review process means you have a formal record of the concerns, and a successful revision after public critique actually strengthens the paper's credibility.

Rejected for incomplete mechanism? You have two options. Either do the additional experiments and resubmit to a high-tier journal, or submit the current version to a journal that values the observation without demanding complete mechanistic resolution. PLOS Biology and PNAS are both more receptive to papers that identify important biological phenomena without fully resolving the underlying mechanism.

Solid paper but eLife wasn't the right fit? Nature Communications is the broadest option, and it publishes enough volume that editorial taste matters less than at smaller journals. The high APC is the main downside.

Strengthen the conceptual framing. Most eLife rejections come down to perceived impact. Before you resubmit anywhere, rewrite your introduction and discussion to make the conceptual advance explicit. Don't bury the significance in the last paragraph of the discussion. State clearly, in the first paragraph, what your paper changes about how we understand the biology.

Close the mechanistic loop. If reviewers or editors flagged an incomplete mechanism, decide whether you can close the loop or whether you should submit to a venue that doesn't require it. Adding a weak mechanistic experiment to satisfy a reviewer is worse than submitting to a journal that values your observational data.

Tighten the narrative. eLife papers typically tell one clean story. If your manuscript tries to cover three related findings, consider whether splitting it into focused papers would strengthen each one. A paper that tries to do too much often ends up not doing enough of any one thing.

Check your figures. eLife and its peer journals put significant weight on data presentation. Cluttered figures, inconsistent formatting, or missing quantification panels can create a negative impression before reviewers engage with the science. Make every figure panel earn its place.

A rejection is a signal, not a verdict. The difference between a paper that gets screened out and one that gets reviewed often comes down to how the story is framed and how clearly the data supports the claims. Run your revised manuscript through a manuscript scope and readiness check to check scope alignment, structural completeness, and formatting before your next submission. Catching presentation issues before editors see them gives your science the best chance of being evaluated on its merits.

Resubmit to the same tier if:

• Reviewers praised the science but identified fixable issues
• The rejection letter mentioned "consider resubmission after revision"
• You can address every concern within 2-3 months
• No competing paper has appeared since your submission

Move to a different journal if:

• The rejection cited scope mismatch, not quality
• Multiple reviewers questioned novelty or significance
• Your timeline needs a decision within 2-3 months
• A specialist journal's readership would value the work more

Reframe before resubmitting anywhere if:

• Reviewers found fundamental methodology concerns
• The narrative needs restructuring, not just polishing
• New experiments or analyses are needed
• The rejection exposed a gap between claims and evidence

In our pre-submission review work with manuscripts targeting eLife, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Methodological rigor concerns that undermine the central conclusion. eLife's public review model means that reviewer concerns become part of the published record, and editors use initial assessment to screen for papers where the methodology would generate irresolvable reviewer objections. We see this failure as the most common pattern in eLife desk rejections we review: papers where the primary conclusion rests on statistical approaches, experimental controls, or sample sizes that trained reviewers would predictably challenge in ways that cannot be resolved with minor revision. In our review of eLife submissions, we find that editors consistently require that the methodology be defensible before the paper enters the reviewed-preprint pipeline.

Advance insufficient relative to recently published work in the same area. eLife positions itself at the top of life sciences publishing and requires findings that move fields forward. We see this pattern in eLife submissions we review address questions that the field has substantially answered in the past 12-24 months, with the new paper adding confirmation, replication, or extension of a question already settled in the literature.

Scope too narrow for eLife's cross-disciplinary life sciences readership. eLife publishes across all of biology, from molecules to ecosystems. Papers addressing questions that matter only within a narrow subfield of cell biology, neuroscience, or genetics without broader biological significance consistently fail the desk scope assessment. We see this failure regularly: highly specialized mechanism papers where the significance statement describes the subfield's next step rather than a principle that would interest a developmental biologist, evolutionary biologist, or computational scientist outside that niche.

Transparency or reproducibility concerns visible from the methods. eLife places particular emphasis on reproducibility and data sharing. We see this pattern in eLife submissions we review: papers without deposited raw data, papers using proprietary analysis pipelines without code availability, or papers where the methods lack sufficient detail for independent replication. These transparency gaps generate consistent editorial concerns under eLife's standards.

SciRev community data for eLife confirms initial assessment decisions typically within days, consistent with the fast editorial triage eLife maintains before entering the reviewed-preprint process.